Validation 70-gene MammaPrint Profile in Japanese Population
29 Years
70 Years
Female
Breast Cancer
Trial Information
Validation 70-gene MammaPrint Profile in Japanese Population
Frozen tumor samples from 140 node-negative, breast cancer patients aged between 29 and 70
years at diagnosis are hybridized on MammaPrint array. Patients were treated with breast
conserving therapy or mastectomy with axillary lymph node dissection between December 1998
and August 2001 at Osaka Medical Center for Cancer and Cardiovascular Diseases. Samples are
evaluated by gene expression profiling for the 70-gene MammaPrint profile and classified as
genomic high risk or genomic low risk.
Inclusion Criteria:
- Breast cancer patients
- Node-negative
- Treated with breast conserving therapy or mastectomy with axillary lymph node
dissection at Osaka Medical Center for Cancer and Cardiovascular Diseases
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
The probability of recurrence free survival (PRFS)
Outcome Time Frame:
5 years
Safety Issue:
No
Principal Investigator
Kikuya Kato, MD, PhD, Prof
Investigator Role:
Study Chair
Investigator Affiliation:
Osaka Medical Center for Cancer and Cardiovascular Diseases
Authority:
Japan: Institutional Review Board
Study ID:
MP-107-RR
NCT ID:
NCT00904566
Start Date:
April 2008
Completion Date:
January 2009
Related Keywords:
- Breast Cancer
- microarray
- gene expression profiling
- MammaPrint
- breast cancer
- Breast Neoplasms
Name | Location |
|---|
